Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years
Annals of Allergy, Asthma & Immunology, ISSN: 1081-1206, Vol: 95, Issue: 3, Page: 254-258
2005
- 125Citations
- 38Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations125
- Citation Indexes121
- 121
- CrossRef78
- Clinical Citations2
- PubMed Guidelines2
- Policy Citations2
- Policy Citation2
- Captures38
- Readers38
- 38
Article Description
The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years. To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than 5 years. Sixty-five children (51 boys and 14 girls; age range, 38-80 months; mean ± SD age, 60 ± 10 years; median age, 60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were house dust mites in 42 patients, grass pollen in 11 patients, olive pollen in 5 patients, Parietaria pollen in 4 patients, and cypress pollen in 3 patients. All adverse reactions and changes in the treatment schedule were compared in 2 subgroups: children 38 to 60 months old and children 61 to 80 months old. The average cumulative dose of SLIT was 36,900 IR. Adverse reactions were observed in 11 children, none of them severe enough to require discontinuation of immunotherapy. Six reactions occurred in the 60 months or younger age group and 7 in the older than 60 months age group, with no differences between these 2 groups. High-dose immunotherapy in children younger than 5 years does not cause more adverse reactions than in children aged 5 to 7 years. There is no reason to forbear studies on safety and efficacy of these preparations in young children.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1081120610612227; http://dx.doi.org/10.1016/s1081-1206(10)61222-7; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=20044392476&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/16200816; http://linkinghub.elsevier.com/retrieve/pii/S1081120610612227; http://api.elsevier.com/content/article/PII:S1081120610612227?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1081120610612227?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S1081120610612227; http://dx.doi.org/10.1016/s1081-1206%2810%2961222-7; https://dx.doi.org/10.1016/s1081-1206%2810%2961222-7
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know